within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BA02_Metformin;

model Metformin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.55,
    Cl = 5.833333333333334e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.063,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0006166666666666666,
    Tlag = 600,
    Vdp = 0.32,
    k12 = 1.2499999999999999e-05,
    k21 = 1.2499999999999999e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Metformin</td></tr><tr><td>ATC code:</td><td>A10BA02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>63</td><td>L</td></tr>
    <tr><td>clearance:</td><td>21</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Metformin is an oral antihyperglycemic agent from the biguanide class, widely used for the treatment of type 2 diabetes mellitus. It is approved today and is considered the first-line pharmacological treatment for type 2 diabetes. Metformin lowers blood glucose primarily by inhibiting hepatic gluconeogenesis and improving insulin sensitivity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Graham, GG, et al., &amp; Williams, KM (2011). Clinical pharmacokinetics of metformin. <i>Clinical pharmacokinetics</i> 50(2) 81–98. DOI:<a href=\"https://doi.org/10.2165/11534750-000000000-00000\">10.2165/11534750-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21241070/\">https://pubmed.ncbi.nlm.nih.gov/21241070</a></p></li><li><p>Scheen, AJ (1996). Clinical pharmacokinetics of metformin. <i>Clinical pharmacokinetics</i> 30(5) 359–371. DOI:<a href=\"https://doi.org/10.2165/00003088-199630050-00003\">10.2165/00003088-199630050-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8743335/\">https://pubmed.ncbi.nlm.nih.gov/8743335</a></p></li><li><p>Dhillon, S (2019). Dapagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> 79(10) 1135–1146. DOI:<a href=\"https://doi.org/10.1007/s40265-019-01148-3\">10.1007/s40265-019-01148-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31236801/\">https://pubmed.ncbi.nlm.nih.gov/31236801</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10BA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Metformin;
